Literature DB >> 26060909

Progressive Myoclonus Epilepsies.

Reetta Kälviäinen1.   

Abstract

The progressive myoclonus epilepsies (PMEs) comprise a group of rare and heterogeneous disorders defined by the combination of action myoclonus, epileptic seizures, and progressive neurologic deterioration. Neurologic deterioration may include progressive cognitive decline, ataxia, neuropathy, and myopathy. The gene defects for the most common forms of PME (Unverricht-Lundborg disease, Lafora disease, several forms of neuronal ceroid lipofuscinoses, myoclonus epilepsy with ragged-red fibers [MERRF], and type 1 and 2 sialidoses) have been identified. The prognosis of a PME depends on the specific disease. Lafora disease, the neuronal ceroid lipofuscinoses, and the neuronopathic form of Gaucher disease have an invariably fatal course. In contrast, Unverricht-Lundborg disease has a much slower progression, and with adequate care many patients have a normal life span. The specific diseases that cause PME are diagnosed by recognition of their age of onset, the associated clinical symptoms, the clinical course, the pattern of inheritance, and by special investigations such as enzyme measurement, skin/muscle biopsy, or gene testing. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2015        PMID: 26060909     DOI: 10.1055/s-0035-1552620

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  16 in total

1.  Polymicrogyria and myoclonic epilepsy in autosomal recessive cutis laxa type 2A.

Authors:  Rony Cohen; Ayelet Halevy; Sharon Aharoni; Dror Kraus; Osnat Konen; Lina Basel-Vanagaite; Hadassa Goldberg-Stern; Rachel Straussberg
Journal:  Neurogenetics       Date:  2016-09-08       Impact factor: 2.660

2.  De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy.

Authors:  Kohei Hamanaka; Eri Imagawa; Eriko Koshimizu; Satoko Miyatake; Jun Tohyama; Takanori Yamagata; Akihiko Miyauchi; Nina Ekhilevitch; Fumio Nakamura; Takeshi Kawashima; Yoshio Goshima; Ahmad Rithauddin Mohamed; Gaik-Siew Ch'ng; Atsushi Fujita; Yoshiteru Azuma; Ken Yasuda; Shintaro Imamura; Mitsuko Nakashima; Hirotomo Saitsu; Satomi Mitsuhashi; Takeshi Mizuguchi; Atsushi Takata; Noriko Miyake; Naomichi Matsumoto
Journal:  Am J Hum Genet       Date:  2020-03-12       Impact factor: 11.025

Review 3.  [Lafora disease: a review of the literature].

Authors:  L Desdentado; R Espert; P Sanz; J Tirapu-Ustarroz
Journal:  Rev Neurol       Date:  2019-01-16       Impact factor: 0.870

4.  Sudden unexpected death with rare compound heterozygous variants in PRICKLE1.

Authors:  Yukiko Hata; Koji Yoshida; Naoki Nishida
Journal:  Neurogenetics       Date:  2018-12-18       Impact factor: 2.660

5.  Focus on progressive myoclonic epilepsy in Berardinelli-Seip syndrome.

Authors:  Silvia Ferranti; Caterina Lo Rizzo; Alessandra Renieri; Paolo Galluzzi; Salvatore Grosso
Journal:  Neurol Sci       Date:  2020-05-21       Impact factor: 3.307

Review 6.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

7.  A novel homozygous splice-site mutation in SCARB2 is associated with progressive myoclonic epilepsy with renal failure.

Authors:  Abolfazl Yari; Reza Molla Ali-Nejad; Nasrollah Saleh-Gohari
Journal:  Neurol Sci       Date:  2021-03-26       Impact factor: 3.307

Review 8.  Emerging treatments for progressive myoclonus epilepsies.

Authors:  Antonella Riva; Alberto Guglielmo; Ganna Balagura; Francesca Marchese; Elisabetta Amadori; Michele Iacomino; Berge Arakel Minassian; Federico Zara; Pasquale Striano
Journal:  Expert Rev Neurother       Date:  2020-03-17       Impact factor: 4.618

Review 9.  Myoclonic Disorders.

Authors:  Olaf Eberhardt; Helge Topka
Journal:  Brain Sci       Date:  2017-08-14

10.  Lafora disease in miniature Wirehaired Dachshunds.

Authors:  Lindsay Swain; Gill Key; Anna Tauro; Saija Ahonen; Peixiang Wang; Cameron Ackerley; Berge A Minassian; Clare Rusbridge
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.